Voxzogo

BioMarin’s Voxzogo shows promise in hypochondroplasia
Pharmaphorum
Fri, 04/12/24 - 11:02 am
Biomarin
Voxzogo
hypochondroplasia
JPM24: BioMarin's new CEO Hardy says top priority is expansion of dwarfism drug Voxzogo
Fierce Pharma
Wed, 01/10/24 - 11:43 am
JPMHC 2024
Alexander Hardy
dwarfism
Voxzogo
BioMarin's dwarfism therapy gets FDA nod for expanded use
Reuters
Mon, 10/23/23 - 09:08 am
BioMarin Pharmaceutical
short-limbed dwarfism
FDA
Voxzogo
With Roctavian as a launching pad, BioMarin looks to up pace of new drug filings
Fierce Biotech
Tue, 09/12/23 - 07:17 pm
Biomarin
Roctavian
hemophilia A
Voxzogo
achrondoplasia
drug development
gene therapy
Voxzogo saves the day for Biomarin
EP Vantage
Tue, 08/1/23 - 10:05 am
Biomarin
hemophilia A
gene therapy
Roctavian
Voxzogo
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Fri, 07/28/23 - 11:46 am
Ipsen
palovarotene
fibrodysplasia ossificans progressiva
Regeneron
CHAPLE disease
pozelimab
Biomarin
Voxzogo
achondroplasia
Santhera Pharmaceuticals
vamorolone
DMD
Springworks
nirogacestat
desmoid tumors
BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia
BioSpace
Wed, 03/8/23 - 09:42 am
Biomarin
BridgeBio
achondroplasia
FDA
Voxzogo
FDA approves first drug for genetic cause of dwarfism
Stat
Fri, 11/19/21 - 11:06 am
Biomarin
FDA
dwarfism
achondroplasia
Voxzogo
BioMarin's new launch Voxzogo could surprise investors and become a blockbuster brand: analyst
Fierce Pharma
Mon, 11/15/21 - 12:24 pm
Biomarin
FDA
Voxzogo
dwarfism
Looking to win back investor confidence, BioMarin preps for its ‘largest launch’
Endpoints
Thu, 10/28/21 - 10:47 am
Biomarin
Voxzogo
drug launches
achrondoplasia
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
Motley Fool
Fri, 08/20/21 - 10:57 am
Biomarin
Voxzogo